05:32 PM EDT, 05/20/2024 (MT Newswires) -- Natarajan Sethuraman, Chief Scientific Officer, on May 16, 2024, sold 18,980 shares in Entrada Therapeutics ( TRDA ) for $287,695. Following the Form 4 filing with the SEC, Sethuraman has control over a total of 190,052 shares of the company, with 190,052 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1689375/000168937524000031/xslF345X03/wk-form4_1716240336.xml